Corcept Therapeutics INC Form 4 insider transactions

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 30,000 shares of common stock on May 28, 2024, according to a Form 4 filing with the SEC.

Director James N. Wilson reported a gift of 2,000 common stock shares and disclaims beneficial ownership except for pecuniary interest.

Director Kimberly Park acquired 30,000 stock options in Corcept Therapeutics on May 17, 2024, exercisable over a one-year period.

Director Joshua M. Murray of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024, exercisable over a one-year period.

Director Daniel N. Swisher Jr. of Corcept Therapeutics acquired 30,000 stock options on May 17, 2024.

Director Gregg H. Alton of Corcept Therapeutics reported the acquisition of stock options on May 17, 2024.

David Mahoney, a director of Corcept Therapeutics, acquired 30,000 stock options on May 17, 2024.

G Leonard Baker Jr., a director of Corcept Therapeutics, acquired 30,000 stock options on May 17, 2024.

Director Gillian Cannon reports the acquisition of stock options in Corcept Therapeutics.

Director James N. Wilson of Corcept Therapeutics acquired 80,000 employee stock options on May 17, 2024.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold 50,000 shares of Corcept Therapeutics (CORT) common stock at $28 per share on May 13, 2024, under a pre-arranged 10b5-1 trading plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 9, 2024, according to a recent SEC filing.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on May 2, 2024, according to a recent SEC filing.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on May 1, 2024, according to a Form 4 filing with the SEC.

Director David L. Mahoney of Corcept Therapeutics exercised stock options, disposed of shares to cover exercise costs and tax liabilities, and transferred shares to a family trust.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on April 4, 2024, according to a Form 4 filing with the SEC.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock on April 1, 2024, pursuant to a 10b5-1 plan.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics (CORT) common stock on March 18 and 19, 2024, according to a Form 4 filing with the SEC.

Joseph Douglas Lyon, Chief Accounting Officer of Corcept Therapeutics, reports stock transactions including share withholding for tax obligations, stock purchases, and vesting of restricted stock units.

Sean Maduck, President of Corcept Endocrinology, reports stock transactions including tax withholding, purchase plan acquisitions, and holdings in related entities.

William Guyer, Chief Development Officer of Corcept Therapeutics, reports the disposal of 604 shares to cover tax obligations related to vesting restricted stock units.

Atabak Mokari, CFO of Corcept Therapeutics, reports transactions involving common stock, including shares withheld for tax obligations, purchases under a company purchase plan, and vesting of restricted stock awards.

Director Daniel N. Swisher Jr. of Corcept Therapeutics exercised stock options and sold the acquired shares on March 1, 2024, according to a Form 4 filing with the SEC.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports stock transactions including tax withholding, purchase plan acquisitions, and restricted stock awards.